Non-steroidal Anti-inflammatory Drugs (NSAIDs) Market Size was valued at USD 2,603 million in 2021 and is poised to grow at a significant CAGR of 0.8% over 2022-2028. Patients with chronic inflammatory arthritis frequently take nonsteroidal anti-inflammatory drugs (NSAIDs). The market for NSAIDs is expected to grow faster as the incidence of arthritis rises. Because of their ability to block prostaglandin formation at the level of the cyclooxygenase enzyme, they are powerful anti-inflammatory and analgesic. In January 2021, NSAIDs have several medications on the market, with many more in the works. Celebrex, an oral drug intended to treat inflammation and discomfort caused by ankylosing spondylitis and other illnesses, was approved by the US Food and Drug Administration. Osteoarthritis, rheumatoid arthritis, juvenile arthritis, acute pain, and primary dysmenorrhea are among the conditions for which the generic medication is prescribed.
Recent Market Developments:
In May 2019, according to Perrigo Company plc, the FDA has approved an Abbreviated New Drug Application (ANDA) for Voltaren Gel.
In April 2018: The USFDA authorized Strides Shasun’s generic Ibuprofen capsules, 200 mg. They are intended to alleviate pain. Pfizer Inc.’s Advil Liqui-Gels 200 mg is a generic version.
There are no reviews yet.